Outcome according to conditioning regimen
| . | Flu/Thio/Bu . | Flu/Thio/Treo . | P . |
|---|---|---|---|
| Evaluable patients, n | 100 | 91 | |
| Primary end point | |||
| Death | |||
| Death, n | 36 | 20 | |
| 3-y OS (95% CI) | 0.63 (0.52-0.72) | 0.76 (0.64-0.84) | .075 |
| Secondary end points | |||
| Any failure | |||
| Relapse, secondary malignancy, or death, n | 47 | 40 | |
| 3-y EFS (95% CI) | 0.52 (0.41-0.61) | 0.51 (0.39-0.62) | .794 |
| Relapse | |||
| Relapse, n | 41 | 37 | |
| 3-y CIR (95% CI) | 0.42 (0.31-0.52) | 0.45 (0.34-0.56) | .920 |
| NRM | |||
| Death in CR, n | 6 | 3 | |
| 3-y NRM (95% CI) | 0.06 (0.02-0.12) | 0.03 (<0.01-0.09) | .406 |
| Acute GVHD by day 100 | |||
| Evaluable, n | 100 | 89 | |
| Grade 0/1, n (%) | 71 (71%) | 74 (83%) | |
| Grade 2, n (%) | 19 (19%) | 7 (8%) | .049∗ |
| Grade 3/4, n (%) | 10 (10%) | 8 (9%) | .813† |
| cGVHD by 3 y | |||
| cGVHD/events without cGVHD/patients, n | 7/45/100 | 4/39/90 | |
| 3-y cumulative incidence of cGVHD (95% CI) | 0.07 (0.03-0.13) | 0.05 (0.02-0.11) | .518 |
| 3-y cumulative incidence of event without cGVHD (95% CI) | 0.46 (0.36-0.56) | 0.48 (0.36-0.59) | .902 |
| GVHD and relapse | |||
| Events/patients, n | 57/99 | 47/88 | |
| 3-y GRFS (95% CI) | 0.41 (0.31-0.51) | 0.41 (0.29-0.52) | .663 |
| Nonhematologic AEs of grade 3/4 at day 100 | |||
| Evaluable, n | 98 | 91 | |
| Grade 3/4, n (%) | 76 (78%) | 63 (69%) | .195 |
| . | Flu/Thio/Bu . | Flu/Thio/Treo . | P . |
|---|---|---|---|
| Evaluable patients, n | 100 | 91 | |
| Primary end point | |||
| Death | |||
| Death, n | 36 | 20 | |
| 3-y OS (95% CI) | 0.63 (0.52-0.72) | 0.76 (0.64-0.84) | .075 |
| Secondary end points | |||
| Any failure | |||
| Relapse, secondary malignancy, or death, n | 47 | 40 | |
| 3-y EFS (95% CI) | 0.52 (0.41-0.61) | 0.51 (0.39-0.62) | .794 |
| Relapse | |||
| Relapse, n | 41 | 37 | |
| 3-y CIR (95% CI) | 0.42 (0.31-0.52) | 0.45 (0.34-0.56) | .920 |
| NRM | |||
| Death in CR, n | 6 | 3 | |
| 3-y NRM (95% CI) | 0.06 (0.02-0.12) | 0.03 (<0.01-0.09) | .406 |
| Acute GVHD by day 100 | |||
| Evaluable, n | 100 | 89 | |
| Grade 0/1, n (%) | 71 (71%) | 74 (83%) | |
| Grade 2, n (%) | 19 (19%) | 7 (8%) | .049∗ |
| Grade 3/4, n (%) | 10 (10%) | 8 (9%) | .813† |
| cGVHD by 3 y | |||
| cGVHD/events without cGVHD/patients, n | 7/45/100 | 4/39/90 | |
| 3-y cumulative incidence of cGVHD (95% CI) | 0.07 (0.03-0.13) | 0.05 (0.02-0.11) | .518 |
| 3-y cumulative incidence of event without cGVHD (95% CI) | 0.46 (0.36-0.56) | 0.48 (0.36-0.59) | .902 |
| GVHD and relapse | |||
| Events/patients, n | 57/99 | 47/88 | |
| 3-y GRFS (95% CI) | 0.41 (0.31-0.51) | 0.41 (0.29-0.52) | .663 |
| Nonhematologic AEs of grade 3/4 at day 100 | |||
| Evaluable, n | 98 | 91 | |
| Grade 3/4, n (%) | 76 (78%) | 63 (69%) | .195 |